Aura Biosciences, Inc Rings the Closing Bell
ABOUT THIS EVENT
Aura Biosciences, Inc (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, visits the Nasdaq MarketSite in Times Square.
In honor of the occasion, Elisabet de los Pino, CEO, rings the Closing Bell.